Emergent to provide development and manufacturing services and secure large-scale manufacturing capacity through 2020 for AstraZeneca’s COVID-19 vax candidate
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.